Central Nervous System B-Cell Lymphoma in Multiple Sclerosis

INTRODUCTION

The association of relapsing remitting multiple sclerosis (RRMS) and the development of primary central nervous system lymphoma (PCNSL) is not clear. Both conditions can initially respond to corticosteroid administration. Patients can be misdiagnosed with a demyelinating disease while actually harboring a neoplastic process. Other patients can potentially develop a neoplastic disease several years following their diagnosis of multiple sclerosis. We report a case of a man with multiple sclerosis who subsequently developed histopathologically-confirmed primary central nervous system lymphoma and discuss the current literature.

CASE REPORT

A 53-year-old man developed acute diplopia and vertigo which persisted for ten weeks and then resolved. A magnetic resonance (MR) imaging study of the brain demonstrated increased T2-weighted signal abnormality in the right middle cerebral peduncle which did not enhance. No treatment was pursued. One year later, following an emergency appendectomy, the symptoms of diplopia and vertigo recurred. These symptoms persisted over the following two months along with dysarthria, dyscoordination and sphincteric dysfunction. A follow-up MR demonstrated progression of the signal abnormalities on the brain MR. He was diagnosed with possible multiple sclerosis and treated with three days of methylprednisolone. The treatment resulted in improvement in his symptoms. He was referred to our institution four months later with the presumptive diagnosis of relapsing remitting multiple sclerosis (RRMS).

Six months later, the patient had some gradual neurological deterioration and underwent a five day treatment with methylprednisolone that resulted in some improvement in his symptoms. Unfortunately, he continued to have progressive symptoms. The patient was scheduled to be enrolled in the CombiRx (interferon beta-1a and glatiramer acetate) trial. Subsequent MR imaging demonstrated increased abnormal signal with cystic changes in the right frontal lobe. The imaging features were considered somewhat unusual for RRMS and he underwent a stereotactic brain biopsy (Figure 1). Biopsy confirmed demyelinating disease with CD68 stain demonstrating numerous macrophages. There was no evidence of malignancy. The patient began the CombiRx trial two months later. The patient tolerated the trial well over the next 12 months without progression of symptoms, until he presented with an acute episode of confusion and...
delusional behavior. Repeat brain MR revealed a diffusely enhancing mass involving both frontal lobes crossing the anterior corpus callosum (Figure 2). Stereotactic brain biopsy revealed a diffuse large B-cell lymphoma expressing CD20 and CD45. The MIB-1 index, reflecting mitotic activity, was 80% in the malignant cells. The patient underwent one cycle of methotrexate chemotherapy and expired one month following the diagnosis of primary central nervous system lymphoma.

**DISCUSSION**

Multiple sclerosis is a chronic demyelinating disease affecting the central nervous system (CNS) and classically presents with exacerbating and relapsing neurological symptoms. Previous to the availability of immunosuppressive and immunomodulating (IS) treatments, reduced rates of cancer were linked to multiple sclerosis. During the past twenty years there has been a significant increase in the number of IS medications available for the treatment of MS (3,5,6,8,17,18). Several reports over the past two decades have suggested an increase in cancer risk amongst MS patients, potentially related to the immunosuppressive therapies (2,7,11-14). Other more recent reports have not found an increased risk of cancer in MS patients (1,3,10). Recently, Lebrun and colleagues reported an exhaustive multicenter review of 7418 MS patients in France evaluating the impact of disease-modifying therapies and the incidence of cancer (10). They found no evidence of an increased risk of cancer following the diagnosis of MS. In fact, they noted that men with MS had a statistically significant decrease in the incidence of cancer. However, there was an increased risk of breast cancer in women receiving more than one IS modality (10).

Primary central nervous system lymphoma (PCNSL) can be confused with multiple sclerosis (4,15). Reportedly, 5%-10% of patients harboring a different disease are misdiagnosed with MS (15). There is no pathognomonic clinical feature, laboratory study or imaging feature for MS. Several conditions including Lyme disease, progressive multifocal leukoencephalopathy, mitochondrial disorders, metabolic deficiencies and lymphoma have been initially confused with MS (4,15). While CNS lymphoma will often show diffuse enhancement with gadolinium administration and demyelinating plaques are much less likely to do so, this is not an absolute finding. In addition, corticosteroid administration will often result in substantial clinical improvement and potentially radiographic resolution of abnormal imaging findings in PCNSL, which can be interpreted as a steroid-induced remission of MS (4).

There is no reported link between the immunosuppressive therapy of interferon beta-1a and glatiramer acetate and the subsequent development of B-cell lymphoma. Interestingly, Krumbholz and co-workers reported their findings on B-cell-activating factor of the tumor necrosis factor (TNF) family (BAFF) (9). Human astrocytes were discovered to secrete BAFF following stimulation with interferon and TNF. They found that BAFF expression was strongly up-regulated to levels similar in lymphatic tissue in multiple sclerosis plaques in brain lesions with B-cell components (9). In addition, BAFF receptors were strongly expressed in PCNSL. They postulated that CNS-produced BAFF may support B-cell survival in inflammatory diseases, such as multiple sclerosis and primary B-cell lymphomas. Similar to our case, Yang and Wu reported a case of a 33-year-old patient with multiple sclerosis who developed central nervous system lymphoma three years following the initial diagnosis (16). Although their patient did receive beta interferon and subsequently developed an
immunocompromised state, there is no compelling evidence of a causal relationship. They postulate that neoplastic transformation may occur in CNS inflammatory disorders such as MS (16).

CONCLUSIONS

The majority of the evidence currently suggests that patients with multiple sclerosis are not at an increased risk for the development of cancer, save possibly breast cancer in women. The differential diagnosis of multiple sclerosis is extensive. There is no conclusive evidence for an association between multiple sclerosis, immunosuppressive treatment and the development of PCNSL. However, continued dependence upon corticosteroid therapy is uncommon in RRMS and should alert the clinician to the possibility of PCNSL. Repeat gadolinium-enhanced imaging and cerebrospinal fluid analysis should aid in distinguishing between RRMS and PCNSL.

REFERENCES